Clinical Trial Update: Study of Pembrolizumab (MK-3475) in Combination With Romidepsin [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating pembrolizumab in combination with romidepsin for recurrent or refractory T-cell lymphomas; the study is currently active b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Cutaneous T-cell Lymphoma
• Mature T-cell Non-hodgman Lymphoma
• Mycosis Fungoides
• Natural Killer Cell Lymphoma
• Peripheral T-cell Lymphoma Not Otherwise Specified
• T-cell Non-hodgkin Lymphoma

Drugs mentioned

• Istodax (romidepsin)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING